Superwarfarins are very long-lasting rodenticides effective in warfarin-resistant rodents at extremely low doses. The consequences of chronic superwarfarin levels in tissues, due to biological half-lives on the order of 20 days, have not been examined. We now characterized the neurological effects of brodifacoum (BDF), one of the most widely used superwarfarins, in adult male Sprague Dawley rats. Dosing curves established the acute oral lethal dose for BDF as 221 6 14 lg/kg. Measurement of tissue BDF levels showed accumulation throughout the body, including the central nervous system, with levels diminishing over several days. Immunocytochemical staining showed that both astrocyte and microglial activation was increased 4 days after BDF administration, as were levels of carbonylated proteins, and neuronal damage assessed by fluorojade B staining. Direct toxic effects of BDF on neurons and glia were observed using enriched cultures of cerebellar neurons and cortical astrocytes. Proteomic analysis of cerebellar lysates revealed that BDF altered expression of 667 proteins in adult rats. Gene ontology and pathway analysis identified changes in several functional pathways including cell metabolism, mitochondria function, and RNA handling with ribosomal proteins comprising the largest group. In vitro studies using primary astrocytes showed that BDF suppressed de novo protein synthesis. These findings demonstrate that superwarfarin accumulation increases indices of neuroinflammation and neuropathology in adult rodents, suggesting that methods which minimize BDF toxicity may not address delayed neurological sequelae.
WHO, 1995) compared with warfarin (estimated between 10 and 300 mg/kg) (USEPA, 1981) is also a consequence of its extremely long biological half-life (approximately 20 days) versus several hours to a few days for warfarin (O'Reilly et al., 1963) , likely due to its strong hydrophobic nature (having a logP value of 8.5 compared with about 2.7 for warfarin).
Unfortunately, as a consequence of the increased use of superwarfarins throughout the world, the occurrence of accidental exposure to these agents has also dramatically increased. Longitudinal reviews from the National Poison Centers estimates up to 15 000 cases of poisoning occur per year within the United Stats alone, mainly due to children ingesting rodent bait (King and Tran, 2015) . Other sources of exposure include those due to accidents during shipping or distribution of rodenticides, as well as to residual amounts following aerial dispersions over large geographic areas to eradicate local pests . Fortunately, treatments for low dose superwarfarin exposure exist, typically infusion with fresh frozen plasma to provide clotting factors, together with vitamin K1 cogeners to maintain physiological levels. Although these protocols are effective to maintain clotting and prevent bleeding, neither treatment reduces tissue levels of the superwarfarins, and therefore treatments, particularly with vitamin K1, can be lengthy, extending for weeks to months.
We previously showed using in vitro studies that BDF, as well as the related superwarfarin difenacoum (DiF), exert direct effects on neuronal and glial cell lines, causing rapid metabolic changes that resulted in cell death within 24 h (Marangoni et al., 2016b) . This suggested that these molecules could induce neuropathological damage following ingestion. Consistent with this, in other studies we showed that chronic treatment of healthy adult mice with warfarin, sufficient to increase clotting time but not cause death, increased glial cell activation throughout the brain (Marangoni et al., 2016a) . In view of the extremely long biological half-life of superwarfarins, and knowledge that they can have detrimental actions in the central nervous system (CNS), we now tested if BDF-induced indices of neuropathology in a rat model of poisoning. Our results show that BDF accumulates in the brain as in other tissues, and is accompanied by significant increases in glial activation as well as signs of neuronal damage. Furthermore, a proteomics analysis reveals that the levels of a large number of proteins involved in general cell processes are altered following exposure to BDF.
MATERIALS AND METHODS
Chemicals. BDF (CPC Scientific, Sunnyvale, California) and DiF (Sigma, St Louis, Missouri) were dissolved at approximately 1.0 mg/ml in ethanol:methanol (50:50 v/v). To confirm the final concentrations, we determined that the absorbance wavelength maximum for BDF is 264 nm with a secondary peak at 309 nm ( Figure 1A ). Using serial dilutions of a stock solution of BDF prepared by dissolving 1.00 mg into 1.00 ml of solvent, we determined that the extinction coefficient at 260 nm is 0.0639 lg/ml/ cm ( Figure 1B ).
Animals. Adult male Sprague Dawley rats were purchased from Harlan (Envigo, Huntingdon, UK). After acclimation, rats were administered BDF at the indicated doses. For gavage, BDF stock solutions in alcohol were diluted into sterile saline to a final volume of 500 ll to provide the required dose. Animals were restrained manually and BDF administered by gavage over a period of 2-3 min. After BDF administration, the rats were housed in a chemical hazard room, to allow collection of waste and bedding contaminated with BDF. All procedures were approved by local IACUC (protocols 13-176 and 13-187).
Tissue preparation. At indicated times, animals were asphyxiated with carbon dioxide in a rodent euthanasia chamber, then transcardially perfused with ice cold phosphate buffered saline (PBS). Brains were removed, dissected at the midline, and 1 hemisphere was postfixed in 4% paraformaldehyde (PFA) for 48 h, followed by 2 days in 30% sucrose solution for cryoprotection. The other hemisphere was dissected into cerebellum (CB) and frontal cortex (CTX), and samples frozen at À80 C until needed.
Measurement of protein carbonylation. Protein carbonyl concentration as an index of oxidative stress was measured using the Protein Carbonyl Colorimetric Assay Kit according to manufacturer's instructions (Cayman Chemical Company, Ann Arbor, Michigan). In brief, samples were homogenized in PBS, centrifuged to remove membranes, then the supernatant treated with streptomycin sulfate to precipitate nucleic acids. The resulting lysates were mixed with 2,4-dinitrophenylhydrazine (DNPH) for 1 h which reacts with protein carbonyl groups to form proteinhydrozones, then unreacted DNPH removed by 3 sequential precipitations using trichloroacetic acid. The amount of protein-hydrozone product was quantified by absorbance at Figure 1 . Determination of BDF absorbance spectra and extinction coefficient. A, A stock solution of BDF was prepared by measuring 1.00 mg of BDF on an Orion Cahn C-33 analytical microbalance with precision of 1.0 lg, then dissolving the BDF into 1.0 ml of ethyl acetate. The BDF was then diluted further in ethyl acetate to the indicated concentrations, and used to obtain absorbance spectrum on a NanoDrop 2000 scanning spectrophotometer with a 1.0 mm path length and 1 nm wavelength accuracy (Thermo Scientific) The peak absorbance was observed at 264 nm with a smaller peak at 309 nm. B, The absorbance of the same BDF solutions were determined at 260 nm in a GeneQuant RNA/DNA spectrophotometer with a 1 cm path length (Pharmacia, Cambridge, UK), from which the extinction coefficient was determined to be 0.0639 lg/ml/cm.
340 nm Mannedorf, Switzerland) . Protein carbonyl levels were determined by comparison to standards, using extinction coefficient of 0.022 mM À1 cm À1 for DNPH, and expressed as nmol carbonyl/gm of protein.
Measurement of serum osteocalcin glutamate carboxylation. Blood samples were collected via tail vein from control and BDFtreated rats at indicated times in citrate containing tubes, centrifuged to obtain serum, then used to measure levels of osteocalcin glutamate carboxylation, an index of GGC activity. Levels of noncarboxylated (Glu) and carboxylated (Gla) osteocalcin were measured by a rat Glu-osetocalcin high sensitive ELISA kit (Takara Bio Inc., Kusatsu, Japan). were added to the plates, or PBS as a negative control. Complete hemolysis was determined by incubation with 0.1%Triton X-100 0.1%). After 1h incubation at 37 C, the plates were centrifuged at 500 g and absorbance at 405 nM of the supernatant was taken as a measure of hemolysis.
Cell culture and treatments. Enriched cultures of primary rat astrocytes and neurons were prepared as described (Kalinin et al., 2013; Madrigal et al., 2009) . In brief, astrocytes were prepared from the frontal cortices of postnatal day 1-2 Sprague Dawley rat pups, grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS and antibiotics (penicillin-streptomycin), and when confluent (approximately 2-3 weeks) shaken to remove adhering microglial cells and oligodendrocyte progenitor cells. Primary cerebellar neurons were prepared from postnatal day 7-8 rat pups, grown in DMEM containing 10% FBS and antibiotics (Gentamycin) for 6-8 days. For treatments, the indicated concentrations of BDF, or equivalent amount of the vehicle (a 50:50 v/v solution of ethanol:methanol) were added to the cells in 96-well plates, and after overnight incubation, cell death was assessed by measuring LDH release using a commercial kit (Promega, Madison, Wisconsin).
HPLC/MS-MS analysis of BDF. Measurement of tissue BDF levels followed the protocol we recently developed . In brief, tissue samples (100 mg) were homogenized in 50 ll saline, internal standard (5 ll of 100 lg/ml DiF) added, then samples extracted using 30% (v/v) acetone in dichloromethane.
Proteins were precipitated by incubation on ice, samples centrifuged at 13 000 Â g for 10 min, supernatants removed, then evaporated to dryness. For analysis, samples were reconstituted in 50 ml of 25% acetone in water, then separated through an Agilent Poroshell 120 EC-C18 column (2.1 Â 150 mm, 2.4 lm) using a Shimadzu (Kyoto, Japan) Nexera chromatography system. BDF was eluted using a 6-min linear gradient from 50% to 100% acetonitrile containing water at 0.55 ml/min. The injection volume was 10 ml, and column temperature was 40 C. Data acquisition and integration was carried out using Shimadzu Lab Solutions software. LC-MS/MS was carried out using a Shimadzu LCMS-8050 triple quadrupole mass spectrometer equipped with negative ion electrospray. BDF was measured using collisioninduced dissociation with selected reaction monitoring (SRM), with argon as the collision gas. Protein preparation for Liquid Chromatograph/Mass Spectroscopy. Protein samples were prepared from whole cerebelli of rats 4 days after treatment with 0.25 mg/kg of BDF. Filter-aided sample preparation was applied to extracts and digested serum proteins from all samples. In brief, 100 lg of protein sample was diluted 10 times in 8 M urea/0.1 M Tris/HCl pH 8.5 then filtered through a 0.22 lM membrane (Millipore, Billerica, Massachusetts). The flowthrough was collected and transferred into a 1.5 mL MicroconYM-30 centrifugal unit (Millipore, Billerica, MA). Protein reduction, alkylation and tryptic digestion were performed step by step in a centrifuge using standard protocols. After overnight digestion at 37 C, the peptides were eluted twice with 150 ll 0.1% formic acid (FA). The digested peptides were aliquoted, dried, and stored at À80 C until further use.
Tandem mass tag labeling. 100 lg of peptides from each sample were used for Amine-reactive 6-plex tandem mass tag (TMT) labeling (Thermo Scientific, San Jose, California). Peptides from each condition (control or BDF treated) were labeled with 1 of the 6-plex TMT tags, following the manufacturer's guide. In brief, the peptides from each sample were re-suspended in dissolution buffer and then incubated with a specific TMT tag for 1 h at room temperature. To each sample, 8 ll of 5% hydroxylamine was added and incubated for 15 min to quench the reaction. Samples with different tags were then pooled for peptide separation. The combined sample was further fractionated using high pH reversed phase HPLC into 90 fractions, followed by further combination into 30 fractions. Fractions were desalted using Nestgroup c18 tips (Southborough, Massachusetts), then dried and redissolved in 0.1% FA for LC-MS/MS analysis.
LC-MS/MS analysis and data process.
Fractions were run on Thermo Fisher Orbitrap Velos Pro coupled with Agilent NanoLC system (Agilent, Santa Clara, California) over a 60 min gradient. RAW files were converted into .mgf files using MSConvert (from ProteoWizard). Database search was carried out using Mascot server (ver 2.5 from Matrix Science) against the Uniprot rat database (ver20160510). Search results from 30 runs were imported into Scaffold (ver 4.75 from Proteome Software, Portland, Oregon) for quantitative analysis. Proteins were identified that had at least 2 peptides, with confidence thresholds of 99% for protein and 95% for peptide. Statistical comparisons were made by False Discovery Rate (FDR) approach, using the 2 stage linear step-up procedure of Benjamini, Krieger and Yekutieli, with Q (the FDR) set to 1%, and assuming that all data rows were sampled from populations with the same variance.
Protein synthesis assay. Nascent protein synthesis was measured using the EZClick Protein Synthesis Monitoring Assay Kit (BioVision, Milpitas, California) according to the manufacturer's instructions. In brief, astrocytes were seeded onto either a 96-well plate or onto chamber slides for imaging. The cells were incubated with 3 lM BDF or vehicle as a control for 22 h. At that time, the cells were incubated for 1 h with the EZ-Click O-propargyl-puromycin (OP-puro) which stops translation and covalently modifies nascent polypeptide chains. Negative controls were pretreated with cycloheximide (CHX) for 30 min before addition of OP-puro. After 2 h, the cells were washed, then incubated for 30 min with a fluorescent azide which conjugates to OP-puro. Cells were washed, then fluorescence measured at 440/490 nm (excitation/emission) for DNA, and 540/580 nm (excitation/emission) for protein labeling in a Synergy H4 plate (BioTek, Winooski, Vermont) . Cells in chamber slides were treated identically, then imaged using a Zeiss Axioplan 2 epifluorescent microscope with an MRm camera and Axiovision v4.7 software using a 40Â objective Data analysis. LD 50 values were determined by Dixon analysis (Dixon and Mood, 1946) . Osteocalcin levels were analyzed by 1-way ANOVA. Hematological parameters, BDF tissue levels, immunocytochemical and immunohistological staining results, and protein synthesis results were analyzed by t tests. Effects of BDF on cell death were analyzed by 2-way ANOVA and Bonferonni post hoc comparisons. Gene ontology (GO) analysis was carried out using the DAVID Bioinformatics Resources 6.7 platform (Huang et al., 2007a,b) software. Cluster analysis was carried out using the STRING platform Szklarczyk and Jensen, 2015) with the evidence parameters set to experimental data (eg, co-purification or co-crystallization studies) or from curated databases (eg, known metabolic pathways, protein complexes, signal transduction pathways), and the confidence level set to 0.40 (medium).
RESULTS
Determination of LD 50 for Acute Oral BDF We first carried out a survival curve for orally administered BDF, since published estimates of LD 50 values for rodents range from 0.16 to 0.93 mg/kg (Redfern et al., 1976; Rennison and Dubock, 1978) , and differ by strain. Following administration of 300 lg/kg, 50% of the animals died by day 4, and 100% died by day 7 (Figure 2A ). Using overall survival after 7 days as criteria, we then determined by Dixon analysis (Dixon and Mood, 1946) that the LD 50 for oral BDF is 221 6 14 lg/kg ( Figure 2B ).
Hematological Effects of BDF Levels of carboxylated glutamate residues (Gla residues) in serum osteocalcin ( Figure 3A ) were significantly decreased, and levels of noncarboxylated glutamate (Glu) levels increased ( Figure 3B ) at 1 day after BDF administration, confirming inhibition of GGC activity. Whole blood analysis showed that after 1 or 4 days, there was no significant decrease in hematocrit ( Figure 4A ), although at 4 days there was a 10% reduction in RBC numbers ( Figure 4B ). Lower hemoglobin levels were observed but those did not reach statistical significance ( Figure 4C ). In contrast, platelet numbers (PLT) were increased at 4 days, and mean platelet volume (MPV) was increased at 1 and 4 days ( Figure 4C ). Upon necropsy we did not observe any large internal hemorrhages but only small (<1 mm), discrete, submucosal lesions ( Figure 4E ) which likely accounts for the small changes observed in hematologic parameters. Direct application of BDF (up to 100 lM) to packed RBCs ( Figure 4F ) did not result in cell lysis (compared with vehicle), ruling out that the observed loss of RBCs was due to direct lysis.
Tissue Distribution of BDF Measurement of tissue BDF levels by HPLC/MS-MS ( Figure 5 ) shows that BDF was detected above background levels in all tissues examined at 1 day after administration, with the highest levels detected in liver. After 4 days, BDF levels decreased in most tissues, although a nonsignificant increase was observed in kidney. After 1 day, BDF was detected in the 2 brain regions examined (frontal CTX and CB), as well as in the spinal cord (SC), at levels comparable to that detected in kidney. After 4 days BDF levels were significantly reduced in the CTX and CB (CB), with a smaller decrease in the SC.
Neurological Effects of BDF
Given evidence for accumulation of BDF in the CNS, and in view of studies showing that chronic warfarin treatment can induce neuropathology (Marangoni et al., 2016a) , we examined brain samples for signs of neuroinflammation and neuronal damage. We focused attention on the CB since both warfarin studies and pilot studies with BDF pointed to greater inflammation in the CB than other regions. Immunocytochemical staining of sagittal sections through the CB (Figure 6 ) showed increased staining for the microglial marker Iba1 and the astrocyte marker GFAP. Quantitative analysis confirmed that both Iba1 ( Figure 6C ) and 250 lg/kg (the oral LD50 dose) of BDF. After 1 and 4 days, the animals were sacrificed, tissues harvested, and BDF levels determined by HPLC/MS/MS. The data is mean 6 sem of 6 rats per group. *p < .05 versus BDF levels measured at day 1. Figure 6D ) staining were significantly increased 4 days after administration of BDF. Analysis of brain lysates showed that BDF also increased protein carbonylation ( Figure 6E ), suggesting that the BDF-dependent increase in glial activation results in increased oxidative stress. Histological analysis using the neuronal marker FJ showed significantly increased staining in the CB due to BDF, consistent with induction of neuronal damage (Figure 7) . In vitro studies using enriched cultures of primary rat cerebellar neurons ( Figure 8A ) and cortical astrocytes ( Figure 8B ) show direct toxic actions of BDF on these cells. Neurons were more sensitive to BDF, since after overnight incubation, significant cell death was observed in neurons at 3 lM BDF, while 30 lM BDF was required to induce significant cell death in astrocytes.
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Proteomics Analysis of BDF Effects in CB
To gain a better understanding of how BDF could influence neurophysiology, we carried out a proteomics analysis of whole cerebellar lysates prepared from control and BDF-treated rats, 4 days after administration. Scaffold software v4.75 was used to analyze Mascot data, and identify proteins whose levels were altered by BDF. At high criteria (minimum of 2 peptides to identify a protein, with confidence thresholds of 99% for protein and 95% for peptide), a total of 4785 unique proteins were identified across the 6 samples analyzed. Comparison of vehicle to BDF-treated samples using a FDR of 0.1% identified 667 proteins whose levels were changed by BDF (Supplementary Table 1 ). The proteins most changed by BDF are shown in Table 1 and include Zdhhc5 (a palmitoyl transferase, reduced about 3-fold); and Nucks1 (nuclear casein kinase and cyclin dependent kinase substrate 1, increased 2.6-fold).
GO analysis was done (Table 2 ) using the DAVID bioinformatics database and STRING cluster analyses. DAVID identified 13 KEGG pathways (with an adjusted Benjamini p-value < .05), and STRING identified 30 KEGG pathways (having a FDR < 0.01). All pathways identified by DAVID were identified by STRING. Visualization of the interrelationships between STRING identified pathways (Supplementary Figure 1) shows several dense clusters which correspond to the top-ranked KEGG pathways. Additional pathways identified by STRING included 3 which reflect general cell functions (metabolic pathways, carbon metabolism, and microbial metabolism), and several involved in metabolism or RNA handling. Aside from the 3 general categories, the ribosomal proteins were most represented with 22 members; in addition 4 other pathways relating to RNA handling (splicing, transport, surveillance, and t-RNA synthesis) were identified. Interestingly, all ribosomal proteins were decreased by BDF; while proteins in the other RNA handling pathways (Spliceosome, tRNA synthesis, RNA surveillance, and RNA transport) were increased or decreased. Cluster analysis (Figure 9) shows the high confidence protein interactions present in 4 of those 5 pathways. Direct in vitro measurement of protein synthesis in primary astrocytes shows that overnight incubation with a low dose of BDF (3 lM, which did not cause any cell death), significantly reduced protein synthesis as compared with vehicle treated cells (Figure 10) .
DISCUSSION
Our results demonstrate that treatment of adult male rats with BDF at a dose that causes 50% death within a few days also increases indices of neuropathology including glial activation, neuronal damage, and changes in the levels of several hundred cerebellar proteins. To our knowledge this is one of the first demonstrations that superwarfarins have actions within the CNS. Together with our previous studies showing that BDF induces kidney damage (Ware et al., 2011) , and that BDF can directly intercalate into biological membranes (Marangoni et al., 2016b) , the current findings suggest that BDF exerts damaging effects on tissues throughout the body independent of its anticoagulant actions. In view of the long biological half-life of BDF (on the order of 20 days), and that current regimens to treat superwarfarin poisoning (fresh frozen plasma and supplementation with vitamin K) do not increase BDF elimination, our findings raise the possibility that neuropathological sequelae may occur despite successful treatment to prevent acute lethality.
The expected mechanism of death following exposure to potent anticoagulant rodenticides like BDF (as well as the parent compound warfarin) is hemorrhage due to the coagulopathy caused by reduction of vitamin K levels. Vitamin K depletion due to inhibition of vitamin K epoxide reductase leads to loss of GGC activity. GGC-dependent carboxylation of clotting factors 2, 7, 9, and 10 is required for clotting, therefore BDF ultimately prevents clotting leading to massive and fatal internal hemorrhage. Although several studies concluded that internal bleeding is the cause of death in some rat strains (Littin et al., 2000; Rennison and Dubock, 1978) , we found lethal doses of BDF did not lead to significant internal bleeding; instead we observed only small (approximately 1 mm), discrete, sub-mucosal hemorrhages. That BDF-reduced vitamin K levels in our studies was confirmed by measurements of serum osteocalcin-Glu and -Gla levels, an indirect measure of GGC activity, consistent with reduced GGC activity. Similarly, measurement of hematological parameters 4 days after administration of BDF showed only small reductions in hematocrit, RBC numbers, and free hemoglobin. These modest reductions could be due to blood loss through the small hemorrhages we observed. Since BDF can have direct cytotoxic actions on cells (Marangoni et al., 2016b) , we also tested if BDF could directly induce RBC hemolysis. However, treatment of packed RBCs with up to 100 lM BDF did not induce hemolysis over that due to treatment with either vehicle or saline. Since anticoagulant induced coagulopathy is typically associated with significant internal bleeding into open cavities, and a corresponding decline of hematocrit, these findings point to other BDF-dependent factors and Figure 8 . Cytotoxic effects of BDF on primary glial and neuronal cultures. The indicated concentrations of BDF or vehicle were added to (A) primary rat cerebellar neurons after 8 days growth in vitro; and (B) primary rat astrocytes that were passaged once at 2 weeks growth at which point they were confluent. After overnight incubation, cell death was assessed by measurement of LDH release. Complete cell death was achieved by incubating the cells in 100 lM BDF, or by full lysis of the cells using detergent. The data is mean 6 SEM of n ¼ 6 per group. *p < .05, 1-way ANOVA and Bonferroni post hoc analysis. Collecting duct acid secretion
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Acyp1,Acyp2,Aldh3a2,Aldh7a1,Fh,Ldhb,Mdh2 mechanisms which contribute to, or are the main cause of death in these animals. Our findings that BDF caused minimal internal bleeding are consistent with previous studies which reported that death in animals due to ingestion of anticoagulants is not always correlated with bleeding. As example, high dose warfarin treatment of albino Oxford rats induced massive hemorrhage in only a single animal after 30 days (Djokic et al., 2013) ; in field studies the rats (Rattus rattus) which died after feeding on BDF bait for at least 6 days showed little hemorrhage, while those that died before 6 days showed no hemorrhage at all (Deoras et al., 1972) ; and in Dark Agouti rats, prothrombin time was not increased after 30 days of drinking 2 mg/l warfarin (Djokic et al., 2013) . In field studies carried out in California, blood and necropsy analyses of bobcats that died after consuming anticoagulants revealed that the majority of deaths were due to manage and not to direct anticoagulant toxicity (Serieys et al., 2015) . In contrast, the same group concluded that mountain lions died directly from the anticoagulant actions due to presence of multiple and extensive hemorrhages, which were absent from bobcats (Uzal et al., 2007) .
Our findings show that 4 days after administration of BDF, there are significant levels of BDF within the CNS, associated with increases in indices of glial activation, neuronal damage, and alterations in protein levels. These findings are in line with studies which showed that vitamin K deficiency, either due to dietary reasons or to prolonged treatment with warfarin, can have neurological consequences including increased risk of cognitive impairment (Annweiler et al., 2015) ; and of Alzheimer's disease (Presse et al., 2008) . Warfarin use has been shown to influence BBB permeability (Haradahira et al., 2000; Ploen et al., 2014) , increase activation of metalloproteinases (Sun et al., 2013) , cause microvascular lesions (Winkler et al., 2014) , and brain hemorrhages (Fernandez et al., 2014) . These changes could in turn allow for influx of other molecules into the CNS that further contribute to pathology.
Effects of BDF on thrombin activation could also contribute to the observed results. Although generally considered a clotting factor acting peripherally, thrombin is also recognized as an inflammatory mediator within the CNS (Grammas and Martinez, 2014) . Thrombin binding to PARs (protease activated receptors) present on glial cells can initiate inflammatory responses (Hanisch et al., 2004) including proinflammatory cytokine release and increased excitotoxicity (Piao et al., 2015) , which has led to testing of thrombin inhibitors as a means to reduce neuroinflammatory events. However, in adult healthy mice, we found that markers of CNS inflammation were reduced by the direct thrombin inhibitor dabigatran, while in contrast they were increased by warfarin, making it unlikely that BDF effects are mediated through inhibition of thrombin activation.
In addition to clotting factors, there are other vitamin K dependent proteins whose activities depend upon GGC activity, some of which are expressed in the CNS and are involved in processes regulating neuronal and glial cell physiology (Ferland, 2012) . In particular, GGC carboxylates Gas6, a ligand for the TAM family of tyrosine kinase receptors (Tyro3, Axl, and Mer) (Prieto et al., 2000) . Gas6 has multiple roles in the CNS, providing neurotrophic support for neurons (Funakoshi et al., 2002) and oligodendrocytes (Shankar et al., 2003) , activating microglial phagocytosis (Grommes et al., 2008) , and suppressing glial inflammatory activation (Binder et al., 2008) . Therefore, reduction of CNS GGC activity could reduce the ability of Gas6 to bind to and activate TAM receptors, leading to loss of its suppression of glial activation. It is also likely that within the CNS, BDF exerts direct effects on neurons and glia, as suggested by our in vitro findings that in enriched primary cultures of neurons and astrocytes, BDF caused cell death after overnight incubation. We previously showed that both BDF and DiF-induced cell death in the human SK-N-MC neuronal cell line and the rat C6 glioma cell line (Marangoni et al., 2016b) . Neuronal death was observed 24 hr after exposure to 20 lM concentrations of either superwarfarin; in contrast C6 glioma cells were relatively resistant to these concentrations which may be related to their higher cholesterol content since cyclodextrin treatment to reduce cholesterol increased their sensitivity to BDF. In the current study, using primary cultures of cerebellar neurons and cortical astrocytes, we also found that neurons were more sensitive to BDF, showing cell death at as low as 3 lM BDF; while primary astrocytes did not show significant cell death until 30 lM BDF was applied. These findings confirm that superwarfarins such as BDF have direct, toxic actions on primary neural cells; which may contribute to the increases detected in glial inflammation and neuronal damage.
Additionally, our previous findings (Marangoni, et al., 2016b) showed that BDF (and other superwarfarins but not warfarin) can intercalate into cell membranes, potentially leading to formation of transient water channels , which would be expected to cause dysregulation of normal cell function and ultimately cell death. We showed that BDF causes a rapid change (within several hours) of metabolic function in glial and neuronal cell lines, suggesting that BDF directly influences mitochondrial processes. Although effects of superwarfarins (or warfarin) on mitochondrial function or metabolism have not been reported, several studies show that vitamin K can act as an election carrier molecule within mitochondria (Lovern and Marbois, 2013) , and that treating cells with vitamin K can induce apoptosis (Shibayama-Imazu et al., 2008) . This raises the possibility that BDF could also act as an electron carrier and thereby modify mitochondrial functions.
Proteomics analysis of whole cerebellar lysates from control and BDF-treated rats revealed changes in 667 proteins (Supplementary Table 1 ). The changes in protein levels ranged from a decrease of about one-third, to an increase of about 3-fold compared with control values. It should be pointed the fold-change reported in Supplementary Table 1 represents the average change calculated from all peptides belonging to the same protein; however, in many cases differentials were identified based on larger changes found in a subset of those peptides, which could reflect changes in protein isoforms or degradation. For this reason, we did not filter out proteins whose average change was <20%, but instead used all 667 proteins for our GO analyses.
The protein most reduced by BDF was Zdhhc5, a member of a family of palmitoyltransferases which share a common catalytic DHHC (Asp-His-His-Cys) motif. These transferases modify intracellular proteins on cysteine residues which increases hydrophobicity facilitating integration into membranes. The precise roles for Zdhhc5 are not yet known; however, in vivo Zdhhc5 is localized to postsynaptic densities, and Zdhhc5 deficiency has been associated with learning and memory deficits (Li et al., 2010) . In neuronal stem cells, Zdhhc5 knockdown prevented palmitoylation of flotillin-2 (Li et al., 2012) , associated with failure of the cells to extend neurites. Interestingly, we observed that flotillin-2 was also slightly, albeit significantly decreased by BDF (Supplementary Table 1 ). In vitro studies have identified 2 other targets of Zdhhc5, the somatostatin receptor 5 (Kokkola et al., 2011) , and STREX, a variant of the large conductance calcium activated potassium BK channel (Tian et al., 2008 (Tian et al., , 2010 . How BDF could modify Zdhhc5 expression is not known; however the hydrophobic nature of BDF suggests it may associate with hydrophobic regions of Zdhhc5 involved in palmitate binding.
The protein most increased by BDF was Nucks1 (nuclear casein kinase and cyclin-dependent kinase substrate 1), a 27 kD protein with roles in DNA damage response. Knockdown of Nucks1 impairs DNA repair, increases cell sensitivity to apoptosis, and increases spontaneous chromatid breaks (Parplys et al., 2015) . Nucks1 overexpression is observed in several cancer tissues, is thought to contribute to tumorogenesis (Gu et al., 2014) , and may have utility as a diagnostic or prognostic marker for certain cancers (Kikuchi et al., 2013) . Nucks has roles in wound healing, since in a corneal burn model, Nucks knockout reduced neovascularization, and reduced expression of proinflammatory cytokines (Poon et al., 2017) . Therefore Nucks may have beneficial roles in certain types of injury, including that associated with BDF induced damage. Relatively little is known regarding Nucks1 in the CNS, other than genome wide association studies which identified Nucks1 variants associated with risk of developing Parkinson's disease (Liu et al., 2011; Wang et al., 2016) , and mood disorders (Savitz et al., 2013) .
The other major KEGG pathways identified as being influenced by BDF are ones involved in RNA handling (ribosome, splicing, transport, surveillance, and tRNA-biosynthesis). In addition to the proteins present in the KEGG database, 9 other ribosome related proteins, 7 other splicing related proteins, and 4 other RNA transport proteins were found altered by BDF (Table 3) . Overall, in the 5 pathways relating to RNA, there were 81 unique proteins (some are in more than 1 pathway) altered by BDF. It should also be noted that of all 29 ribosomal proteins, all but were (Rrbp1) were decreased by BDF. Whether BDF can bind to nucleic acids such as RNA is not known; but such interactions could underlie not only changes in RNA related proteins, but also in amino acid utilization and hence metabolism. Our in vitro findings that BDF reduces de novo protein synthesis in primary astrocytes is consistent with reductions in ribosomal proteins, further suggesting that BDF could influence cell biology by interfering with basic catabolic processes.
Our proteomics results of rat CB complement a recent metabolomics analysis of plasma from BDF treated rats (Yan et al., 2016) . In that study, 24 metabolites were identified as potential biomarkers for BDF poisoning, primarily involved in glucose, lipid, or amino acid metabolism. Of the 24, about half occur within pathways that were also identified in our (Table 4) . Although the metabolite changes in plasma were attributed to kidney damage, our results suggest that BDF may also cause dysregulation of the pathways responsible for those changes in serum.
In summary, our findings demonstrate that the superwarfarin BDF not only has peripheral actions, but accumulates within the CNS with significant consequences. Whether those actions depend upon inhibition of GGC in the CNS, or are due to direct effects of BDF on cells remains to be determined. The current treatment for BDF poisoning (either accidental or intentional) comprises fresh frozen plasma to provide clotting factors, followed by supplementation with vitamin K (menadione) for weeks to months, sometimes extending to over a year. Although these methods are effective to restore coagulation and prevent death, neither reduces tissue levels of BDF which are naturally eliminated with a biological half-life of 20 days or longer. These methods therefore do not mitigate any risk of neurological (or other tissue) damage due to the long-lasting residual amounts of BDF; this suggests that additional methods designed to scavenge or inactivate BDF should be evaluated.
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